These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 27110368)

  • 21. Basal insulin titration by the app.
    Vangoitsenhoven R; Van der Schueren B
    Lancet Reg Health Eur; 2023 Oct; 33():100720. PubMed ID: 37953999
    [No Abstract]   [Full Text] [Related]  

  • 22. INPATIENT HYPOGLYCEMIC EVENTS IN A COMPARATIVE EFFECTIVENESS TRIAL FOR GLYCEMIC CONTROL IN A HIGH-RISK POPULATION.
    Welsh N; Derby T; Gupta S; Fulkerson C; Oakes DJ; Schmidt K; Parikh ND; Norvell JP; Levitsky J; Rademaker A; Molitch ME; Wallia A
    Endocr Pract; 2016 Sep; 22(9):1040-7. PubMed ID: 27124695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
    Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
    Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report.
    Simonson GD; Holt EH; Grady M; Hurrell G; Gaudiani LM; Bergenstal RM
    Clin Diabetes; 2024; 42(4):550-560. PubMed ID: 39429460
    [No Abstract]   [Full Text] [Related]  

  • 25. The Clinical Definition of Overbasalization.
    Davidson MB
    Clin Diabetes; 2021 Oct; 39(4):411-414. PubMed ID: 34866782
    [No Abstract]   [Full Text] [Related]  

  • 26. Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.
    Cowart K
    Clin Diabetes; 2020 Jul; 38(3):304-310. PubMed ID: 32699482
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical Use of IDegLira: Initiation to Titration After Basal Insulin.
    Warren M; Steel D
    Clin Diabetes; 2020 Jan; 38(1):62-70. PubMed ID: 31975753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin Initiation and Titration in Patients With Type 2 Diabetes.
    Chun J; Strong J; Urquhart S
    Diabetes Spectr; 2019 May; 32(2):104-111. PubMed ID: 31168280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
    Peters AL; Piletič M; Ejstrud J; Salvesen-Sykes K; Snyder J; Bowering K
    Diabetes Obes Metab; 2019 Jul; 21(7):1752-1756. PubMed ID: 30924578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value.
    Siegmund T; Borck A; Zisman A; Bramlage P; Kress S
    J Clin Transl Endocrinol; 2018 Dec; 14():34-38. PubMed ID: 30416973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.
    Zisman A; Dex T; Roberts M; Saremi A; Chao J; Aroda VR
    Diabetes Ther; 2018 Oct; 9(5):2155-2162. PubMed ID: 30218434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.
    Valentine V; Goldman J; Shubrook JH
    Diabetes Ther; 2017 Aug; 8(4):739-752. PubMed ID: 28721686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin.
    Zisman A; Morales F; Stewart J; Stuhr A; Vlajnic A; Zhou R
    BMJ Open Diabetes Res Care; 2016; 4(1):e000171. PubMed ID: 27110368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose.
    Kress S; Borck A; Zisman A; Bramlage P; Siegmund T
    Diabetes Metab Syndr Obes; 2021; 14():1215-1222. PubMed ID: 33776458
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.